IRadimed vs Utah Medical Products
IRMD and UTMD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRMD and UTMD compare
IRadimed is the larger company, worth 4.8 times as much as Utah Medical Products ($1.1B against $229M).
On earnings, Utah Medical Products is cheaper: it trades at 21.5× trailing earnings, against 45.6× for IRadimed.
Both pay dividends: IRadimed yields 1.1% and Utah Medical Products 1.7%.
IRadimed scores higher on the StockData Score (19 against 10 for Utah Medical Products), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRMD | UTMD |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $229M |
| Share price | $85.35 | $71.97 |
| Change, 1 year | −1.2% | 28.1% |
| Change, 5 years | 119% | −37.8% |
| Beta (5Y) | 0.75 | 0.48 |
| Employees | 166 | 140 |
| StockData Score | ||
| Total score | 19 (better) | 10 |
| Valuation score | 0 | 3 (better) |
| Growth score | 4 (better) | 0 |
| Performance score | 6 (better) | 1 |
| Health score | 6 (better) | 4 |
| Dividend score | 3 (better) | 2 |
| Valuation | ||
| P/E | 45.6× | 21.5× (better) |
| P/S | 12.2× | 6.6× (better) |
| P/B | 10.3× | 1.9× (better) |
| EV/EBITDA | 33.7× | 13.8× (better) |
| P/FCF | 41.8× | 21.1× (better) |
| PEG | 2.32 | – |
| FCF yield | 2.4% | 4.7% (better) |
| Fair value | $53.46 | $76.38 |
| Margin of safety | −59.7% | 5.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.0% | – |
| Revenue growth, 5Y average | 21.5% (better) | −1.8% |
| Net income growth (TTM) | 13.2% | – |
| EPS growth (TTM) | 13.3% | – |
| EPS growth, 5Y average | 73.9% (better) | 3.4% |
| Profitability | ||
| Gross margin | 75.5% (better) | 57.7% |
| Operating margin | 32.3% (better) | 29.9% |
| Net margin | 26.8% | – |
| FCF margin | 29.3% | 31.1% (better) |
| Return on equity | 23.4% | – |
| Return on invested capital | 52.3% (better) | 23.7% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Net debt / EBITDA | – | −8.14 |
| Current ratio | 8.99 | 21.23 (better) |
| Altman Z-score | 48.00 (better) | 29.21 |
| Piotroski F-score | 6 | – |
| Dividends and buybacks | ||
| Dividend yield | 1.1% | 1.7% (better) |
| Payout ratio | 67.6% | – |
| Buyback yield | – | 0.83% |
| Shareholder yield | 1.1% | 2.6% (better) |
| Ownership | ||
| Held by institutions | 61.4% | 72.8% |
| Held by insiders | 35.5% | 7.3% |
| Insider net buying, 12 months | −$16.0M | $66.8K (better) |
| Short interest, % of float | 7.2% | 5.1% |
Go deeper
- IRMD stock overview
- IRMD income statement
- IRMD valuation and score
- UTMD stock overview
- UTMD income statement
- UTMD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.